<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004381</url>
  </required_header>
  <id_info>
    <org_study_id>199/12021</org_study_id>
    <secondary_id>RUH-0330795A</secondary_id>
    <nct_id>NCT00004381</nct_id>
  </id_info>
  <brief_title>Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Compare the efficacy of preventive vs. therapeutic tin mesoporphyrin in direct
      Coombs' test-positive ABO hemolytic disease of the newborn and glucose-6-phosphate
      dehydrogenase deficiency in infants living in Greece.

      II. Assess the safety of tin mesoporphyrin in high-risk newborns.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients are stratified by gestational age and sex, and randomly assigned
      in pairs per stratum.

      One group receives a preventive dose of tin mesoporphyrin. Another group receives a
      therapeutic dose of tin mesoporphyrin according to the plasma bilirubin concentration.

      Patients in either group may be treated concurrently with phototherapy or exchange
      transfusion if clinically indicated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Glucosephosphate Dehydrogenase Deficiency</condition>
  <condition>Hyperbilirubinemia</condition>
  <condition>Hemolytic Disease of Newborn</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tin mesoporphyrin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Hyperbilirubinemia associated with either of the following:
        Direct Coombs' test-positive ABO hemolytic disease of the newborn Glucose-6-phosphate
        dehydrogenase deficiency --Prior/Concurrent Therapy-- No maternal phenobarbital in last
        month of pregnancy --Patient Characteristics-- Performance status: Not specified
        Hematopoietic: Not specified Hepatic: Not specified Renal: No congenital renal abnormality
        Cardiovascular: No congenital heart abnormality Pulmonary: No asphyxia requiring assisted
        ventilation at delivery Other: Gestational age more than 210 days Birth weight at least
        1500 g No other major congenital abnormality, i.e.: Central nervous system Chromosomal
        Gastrointestinal No evident or suspected congenital infection, e.g.: Cytomegalovirus Herpes
        Rubella Syphilis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Attallah Kappas</last_name>
    <role>Study Chair</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New England Medical Center Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockefeller University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-6399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>glucose-6-phosphate dehydrogenase deficiency</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>hemolytic disease</keyword>
  <keyword>hyperbilirubinemia</keyword>
  <keyword>neonatal disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
    <mesh_term>Erythroblastosis, Fetal</mesh_term>
    <mesh_term>Glucosephosphate Dehydrogenase Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tin mesoporphyrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

